-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Benzinga·08/10/2026 14:07:21
Listen to the news
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.